Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Gilead is a biopharmaceutical company focused on HIV, viral hepatitis, oncology, and inflammation. The reporting period was characterized by significant strategic acquisitions (Arcellx, Tubulis, Ouro Medicines) and a major impairment charge related to the discontinuation of a Phase 3 oncology study.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $7,803 | $14,763 |
| Net (Loss) Income | $(10,496) | $(8,475) |
| Diluted (Loss) EPS | $(8.45) | $(6.82) |
| Operating Cash Flow | N/A | $6,117 |
| Cash and Equivalents (End of Period) | $3,179 | $3,179 |
| Total Debt (Net) | $26,246 | $26,246 |
| Product Gross Margin | 79.3% | 79.3% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 10% ($7.8B) for the quarter and 7% ($14.8B) for the six months compared to the same periods in 2025. Growth was driven by higher sales of HIV products (Biktarvy, Descovy), Trodelvy, and Livdelzi, partially offset by declines in Veklury and Cell Therapy sales.
- Significant Losses: The company reported a net loss of $10.5B for the quarter and $8.5B for the six months, a sharp reversal from net income of $2.0B and $3.3B in the prior year periods. This was primarily due to non-recurring charges.
- Acquired IPR&D Expenses: Expenses surged to $11.2B for the quarter and $11.3B for the six months, driven by the acquisitions of Arcellx ($7.0B charge), Tubulis ($3.1B charge), and Ouro Medicines ($1.0B net charge).
- Impairment Charges: A $1.75B impairment charge was recorded for in-process research and development (IPR&D) assets related to the discontinued Phase 3 EVOKE-03 study of Trodelvy in non-small cell lung cancer (NSCLC).
- Debt Activity: The company issued $3.0B in senior unsecured notes in May 2026 and entered a $4.7B term loan facility, borrowing $1.1B. It also repaid $2.75B of notes maturing in March 2026.
Guidance, Outlook, and Risks
- Management Commentary: Management highlighted the strategic value of the Arcellx, Tubulis, and Ouro Medicines acquisitions in strengthening the oncology and inflammation pipelines. The discontinuation of the EVOKE-03 study was based on Data Monitoring Committee recommendations regarding progression-free survival and overall survival data.
- Regulatory Updates:
- Hepcludex: Received FDA accelerated approval for chronic hepatitis delta virus infection.
- Trodelvy: Received FDA approval for first-line treatment of metastatic triple-negative breast cancer (mTNBC) and European Commission marketing authorization.
- Yeztugo: FDA accepted a supplemental NDA for a once-weekly oral formulation for HIV PrEP.
- Risks and Contingencies:
- Legal Proceedings: Ongoing antitrust litigation regarding HIV drugs (Phase II claims pending) and product liability lawsuits related to kidney/bone injuries from Viread/Truvada. A trial for the federal product liability bellwether is scheduled for March 2027.
- Regulatory/Policy: Risks associated with the Inflation Reduction Act (IRA) regarding Medicare price negotiation (Biktarvy selected for 2028) and potential tariffs on pharmaceutical imports under Section 232.
- Operational: Integration risks from recent acquisitions and potential supply chain disruptions.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost synergies for integrating Arcellx, Tubulis, and Ouro Medicines, given the $11.3B in immediate IPR&D charges.
- IPR&D Impairment: Confirm the finality of the $1.75B impairment related to the Trodelvy NSCLC study and assess the impact on future oncology pipeline valuations.
- Liquidity Position: Monitor cash burn relative to the $3.2B cash balance and the $26.2B debt load, especially given the heavy capital deployment in Q2 2026.
- Legal Exposure: Track the status of the antitrust Phase II trial and the product liability bellwether trial scheduled for March 2027.
- Revenue Sustainability: Assess the durability of HIV revenue growth (Biktarvy, Descovy) in the face of potential generic competition and IRA price negotiations starting in 2028.